News

Morepen Laboratories announced the successful completion of a United States Food and Drug Administration (USFDA) inspection at its Masulakhanna (HP) facility, with Zero observations (NIL Form 483). This marks the Fourth consecutive NIL 483 inspection for Morepen over the past eight years, underscoring the Company`s unwavering commitment to global quality and regulatory standards.

Morepen Laboratories has repaid working capital demand loan facility and cash credit limit availed from Kotak Mahindra Bank amounting to Rs 79 crore on 02 March 2026. Powered by Capital Market - Live News

Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs 825 crore (USD 91 million) from a leading global pharma major. Supplies under the mandate are expected to commence within the next 4-5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes.Powered by Capital Market - Live News

Net profit of Morepen Laboratories rose 3.07% to Rs 27.51 crore in the quarter ended December 2025 as against Rs 26.69 crore during the previous quarter ended December 2024. Sales rose 6.93% to Rs 484.16 crore in the quarter ended December 2025 as against Rs 452.78 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales484.16452.78 7 OPM %9.577.98 - PBDT45.8040.14 14 PBT35.4235.21 1 NP27.5126.69 3 Powered by Capital Market - Live News

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 10 February 2026.Powered by Capital Market - Live News